LTI 03
Alternative Names: Caveolin-1 scaffold protein-derived 7-amino acid peptide; Caveolin-1 scaffolding protein derived peptide; CSP7; LTI-03Latest Information Update: 24 Aug 2026
At a glance
- Originator Lung Therapeutics; University of Texas at Tyler
- Developer Rein Therapeutics
- Class Alcohols; Amides; Amino acids; Antifibrotics; Benzene derivatives; Carboxylic acids; Peptides
- Mechanism of Action Caveolin 1 replacements
-
Orphan Drug Status
Yes - Idiopathic pulmonary fibrosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis
Most Recent Events
- 20 Aug 2026 LTI 03 receives Fast Track designation for Idiopathic pulmonary fibrosis [Inhalation,Powder] in USA
- 21 Jul 2026 Phase-II clinical trials in Idiopathic pulmonary fibrosis in Germany (Inhalation) (NCT06968845)
- 02 Feb 2026 Phase-II clinical trials in Idiopathic pulmonary fibrosis in United Kingdom (Inhalation) (NCT06968845)